The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer

点击翻译按钮获取中文摘要

PROJECT SUMMARY / ABSTRACT Since the inception of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) Consortium, the Mayo Clinic team has been an active participant, including leadership roles, in multiple initiatives. A key priority of the Consortium is the facilitation of mechanism-based research of chronic pancreatitis, pancreatogenic diabetes mellitus, and pancreatic cancer through systematically collected clinical measures in longitudinal cohort studies linked with biospecimens. The goal of the Mayo Clinic team is to contribute meaningfully to the most useful longitudinal cohorts that will increase our understanding of clinical, epidemiological, and biological characterization of patients with these conditions. The primary longitudinal cohort initiatives (outlined in the PAR) to which Mayo Clinic will continue to contribute are PROCEED and NOD. Mayo Clinic investigators will also extend ancillary studies in PROCEED (salivary biomarkers and internet based pain management techniques for pain in chronic pancreatitis (IMPACT)) that leverage the extensive infrastructure in place. The Consortium has defined three Working Groups (WG) in which Mayo Clinic investigators contribute and provide leadership (chronic pancreatitis (CP), Type 3c diabetes mellitus (T3cDM); pancreatic cancer-DM WG. Our contribution includes solid accrual rates for these studies to date, and successful completion of one ancillary study by the PI, active participation in the design of the NOD cohort and subsequent modifications, and extending accrual for DETECT. Using the existing, highly productive infrastructure we have established, our Specific Aims are to: 1) Continue to prospectively enroll and expand accrual of 100 Mayo patients into the PROCEED cohort. Using the clinical research infrastructure in place, we will also enroll chronic pancreatitis patients and subjects into ancillary studies within the CPDPC that include, among others: salivary biomarkers, MINIMAP, and PAIR. 2) Continue to prospectively enroll and expand accrual of 1,322 newly diagnosed diabetes patients into the NOD study. 3) Continue to lead and extend prospective accrual of 60 Mayo participants into the DETECT study. To accomplish these aims, we will implement and identify new strategies to improve recruitment into the main studies as well as ancillary studies at Mayo Clinic while providing to the CPDPC the scientific, clinical and recruitment experience of our investigators.